Advertisement
Advertisement
U.S. markets close in 52 minutes
Advertisement
Advertisement
Advertisement
Advertisement

The Greater Cannabis Company, Inc. (GCAN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00100.0000 (0.00%)
As of 02:30PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0010
Open0.0011
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0009 - 0.0011
52 Week Range0.0009 - 0.0075
Volume1,806,190
Avg. Volume7,426,350
Market Cap533,638
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GCAN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GREATER CANNABIS CO INC
    Analyst Report: Fluor CorporationFluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. The firm serves a wide range of end markets including oil and gas, chemicals, mining, metals, and transportation. The company’s business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor employs over 40,000 workers in more than 60 countries. The company generated $12.4 billion in revenue in 2021.
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • GlobeNewswire

    GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special

    weed.6 GCAN Advisor to be Featured in CNN Documentary The 6th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19th at 9pm ET BALTIMORE, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics is pleased to announce that its strategic advisor and developer of GCANRx’s licensed cannabinoid therapeutic, Dr. Adi Aran,

  • GlobeNewswire

    GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor

    Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies. BALTIMORE, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics is pleased to announce that it has appointed Dr. Adi Aran, M.D., Head of Pediatric Neurology at Shaare Zedek Medical center, to

  • GlobeNewswire

    GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

    BALTIMORE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has begun the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company’s announcement of the preclinical study follows the signing of a license and research agreement with Shaare Zedek Scientific related to th

Advertisement
Advertisement